Prime Medicine (PRME) Competitors $6.26 -0.19 (-2.99%) As of 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME vs. INDV, CNTA, APLS, XENE, GMTX, RARE, CGON, QURE, IMVT, and TARSShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Indivior (INDV), Centessa Pharmaceuticals (CNTA), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Gemini Therapeutics (GMTX), Ultragenyx Pharmaceutical (RARE), CG Oncology (CGON), uniQure (QURE), Immunovant (IMVT), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors Indivior Centessa Pharmaceuticals Apellis Pharmaceuticals Xenon Pharmaceuticals Gemini Therapeutics Ultragenyx Pharmaceutical CG Oncology uniQure Immunovant Tarsus Pharmaceuticals Indivior (NASDAQ:INDV) and Prime Medicine (NYSE:PRME) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability. Do insiders & institutionals hold more shares of INDV or PRME? 60.3% of Indivior shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 22.7% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is INDV or PRME more profitable? Indivior has a net margin of 6.65% compared to Prime Medicine's net margin of 0.00%. Indivior's return on equity of -86.28% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Indivior6.65% -86.28% 16.26% Prime Medicine N/A -107.87%-74.97% Do analysts prefer INDV or PRME? Indivior currently has a consensus target price of $22.00, suggesting a potential downside of 8.91%. Prime Medicine has a consensus target price of $8.92, suggesting a potential upside of 42.51%. Given Prime Medicine's higher possible upside, analysts plainly believe Prime Medicine is more favorable than Indivior.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has higher valuation and earnings, INDV or PRME? Indivior has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndivior$1.17B2.84$2M$0.6238.95Prime Medicine$4.96M169.73-$198.13M-$1.56-4.01 Which has more volatility & risk, INDV or PRME? Indivior has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Does the media prefer INDV or PRME? In the previous week, Prime Medicine had 2 more articles in the media than Indivior. MarketBeat recorded 4 mentions for Prime Medicine and 2 mentions for Indivior. Prime Medicine's average media sentiment score of 0.63 beat Indivior's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryIndivior beats Prime Medicine on 9 of the 16 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$841.76M$357.34M$9.07B$21.87BDividend YieldN/AN/A5.69%3.58%P/E Ratio-3.05N/A85.9129.64Price / Sales169.73446.24536.1262.45Price / CashN/A22.4437.9224.43Price / Book4.573.8913.004.61Net Income-$198.13M-$133.30M$3.30B$1.01B7 Day Performance-6.19%1.84%4.64%-0.38%1 Month Performance51.87%16.87%9.82%2.34%1 Year Performance75.76%21.78%84.78%14.36% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.5637 of 5 stars$6.26-3.0%$8.92+42.5%+70.6%$841.76M$4.96M-3.05234INDVIndivior2.9656 of 5 stars$22.73-1.9%$22.00-3.2%+145.1%$3.13B$1.17B36.661,051News CoverageAnalyst ForecastCNTACentessa Pharmaceuticals2.8897 of 5 stars$23.00-1.0%$32.38+40.8%+38.7%$3.08B$6.85M-12.85200Analyst ForecastAPLSApellis Pharmaceuticals4.0675 of 5 stars$24.36+2.4%$33.29+36.7%-9.1%$3.08B$781.37M-13.38770Analyst ForecastXENEXenon Pharmaceuticals2.8952 of 5 stars$39.55-0.2%$53.30+34.8%-4.3%$3.05B$9.43M-11.14210News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGMTXGemini TherapeuticsN/A$67.78+2.9%N/A+43.4%$2.94BN/A-67.7830RAREUltragenyx Pharmaceutical4.3851 of 5 stars$30.19-3.3%$81.50+170.0%-42.1%$2.91B$560.23M-5.461,294Analyst ForecastCGONCG Oncology2.3258 of 5 stars$38.13-4.2%$56.55+48.3%+16.9%$2.91B$1.14M-21.5461News CoverageAnalyst ForecastQUREuniQure3.1274 of 5 stars$52.91-3.7%$71.75+35.6%+913.0%$2.90B$14.34M-13.50500Trending NewsAnalyst ForecastAnalyst RevisionIMVTImmunovant1.8835 of 5 stars$16.55-2.1%$33.20+100.6%-45.7%$2.88BN/A-5.81120TARSTarsus Pharmaceuticals0.7836 of 5 stars$67.71+3.9%$66.67-1.5%+105.1%$2.86B$182.95M-29.0650Analyst Forecast Related Companies and Tools Related Companies Indivior Alternatives Centessa Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Ultragenyx Pharmaceutical Alternatives CG Oncology Alternatives uniQure Alternatives Immunovant Alternatives Tarsus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
